Curriculum Vitaes

hayashi masamichi

  (林 正道)

Profile Information

Affiliation
School of Medicine Faculty of Medicine, Fujita Health University
Degree
博士(医学)

Other name(s) (e.g. nickname)
許可しない
J-GLOBAL ID
201501009775390763
researchmap Member ID
7000013249

Misc.

 14
  • Sumito Isogai, Masamichi Hayashi, Naoki Yamamoto, Mariko Morishita, Tomoyuki Minezawa, Takuya Okamura, Tami Hoshino, Mitsushi Okazawa, Kazuyoshi Imaizumi
    Allergology international : official journal of the Japanese Society of Allergology, 62(3) 367-73, Sep, 2013  Peer-reviewed
    BACKGROUND: Although a challenge test using non-steroidal anti-inflammatory drugs (NSAIDs) is crucial for diagnosis of aspirin-induced asthma (AIA), it also has drawbacks in terms of possible side effects. Therefore, alternative in-vitro diagnostic methods for AIA are awaited. METHODS: Nineteen stable non-AIA patients (9 males and 10 females; mean age, 49.4 ± 4.8 years), and 20 AIA patients (9 males and 11 females; mean age, 51.1 ± 4.8 years) were enrolled in this study. CD11b and CD16 expressions on the peripheral-blood granulocytes after administration of aspirin and different concentrations of PGE2 in vitro were examined using flowcytometry. RESULTS: Aspirin induced a significant increase in CD11b expression on eosinophils (CD16 negative granulocytes) in 19 AIA patients and one non-AIA patient. Increase in CD11b expression on eosinophils by aspirin administration was suppressed by PGE2 in a dose-dependent manner. CONCLUSIONS: The measurement of CD11b expression on peripheral-blood eosinophils showed very high sensitivity and specificity of (-95%) in diagnosing AIA. Although this method requires laboratory facilities for flowcytometry, it may be very useful in diagnosis of AIA without side effects. In addition, PGE2 may be involved in regulation of CD11b expression on eosinophils by aspirin administration.
  • Hideyasu Shimizu, Masamichi Hayashi, Yuji Saito, Yuki Mieno, Yasuo Takeuchi, Fumihiko Sasaki, Hiroki Sakakibara, Kensei Naito, Mitsushi Okazawa
    Cough, 9(1) 4, Feb 7, 2013  Peer-reviewed
    Background: Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic cough vary depending on the clinical settings and the particular interests of investigators.Objectives: The purposes of this study were first to categorize the etiology of chronic cough by its response to systematic diagnostic treatments starting from the β2 agonist and second to sub-categorize β2 agonist responsive cough (BRC) by the airway hyperresponsiveness.Methods: One hundred and eighty-four never-smokers received the maximal dose of procaterol to diagnose BRC. BRC was sub-categorized into two groups with or without airway hyperresponsiveness measured by the methacholine challenge test. Sinobronchial syndrome (SBS) was diagnosed by postnasal drip symptoms and by the response to clarythromycin and carbocysteine. Atopic cough (AC) was diagnosed by the evidence of atopy and the response to cetirizine hydrochloride. Gastroesophageal reflux disease (GERD) was diagnosed by the response to rabeprazole sodium. Since we did not investigate eosinophil counts in the tissue or in the induced sputum, no diagnosis of eosinophilic bronchitis was made.Results: One hundred and nine patients had BRC. Twenty-three of them had bronchial asthma (BA), 53 had cough variant asthma (CVA) and 33 had non-hyperresponsive BRC (NHBRC). Thirty-one patients had GERD, 27 had AC and 14 had SBS. Twenty-five patients had more than one diagnosis in combination, while 6 had other miscellaneous diseases. Twelve patients were undiagnosed and 11 dropped out of the study.Conclusions: The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan.Trial registration: University hospital medical information network (UMIN 000007483). © 2013 Shimizu et al. licensee BioMed Central Ltd.
  • 磯谷澄都, 今泉和良, 岡澤光芝, 林 正道, 峯澤智之
    平成24年度厚生労働科学研究費補助金 難治性疾患等克服研究事業(免疫アレルギー疾患等予防・治療研究事業 免疫アレルギー疾患分野), 69, 2013  
  • 磯谷澄都, 今泉和良, 岡澤光芝, 林 正道, 峯澤智之
    平成24年度 厚生労働科学研究費補助金 難治性疾患等克服研究事業 免疫アレルギー疾患等予防・治療研究事業 研究報告書(免疫アレルギー疾患分野), 288-292, 2013  
  • 山口哲平, 中西 亨, 磯谷澄都, 林 正道, 星野多美, 魚津桜子, 森下真梨子, 峯澤智之, 岡澤光芝, 今泉和良
    肺癌, 53(4) 318-323, 2013  Peer-reviewed
  • Masamichi Hayashi, Tomoyuki Minezawa, Kazuyoshi Imaizumi, Yoshihiro Sobue, Eiichi Watanabe, Yukio Ozaki, Mitsushi Okazawa
    Respiration; international review of thoracic diseases, 86(3) 252-3, 2013  Peer-reviewed
  • 磯谷澄都, 今泉和良, 岡澤光芝, 林 正道, 岡村拓哉, 峯澤智之
    平成23年度総括・分担研究報告書、厚生労働科学研究・免疫アレルギー疾患等予防・治療研究事業, 23-26, 2012  
  • 榊原博樹, 林 正道, 三重野ゆうき, 佐々木文彦
    平成23年度研究報告書、厚生労働科学研究費・循環器疾患・糖尿病等生活習慣病対策総合研究事業, 101-108, 2012  
  • 榊原博樹, 井水ひろみ, 三重野ゆうき, 林 正道, 多田利彦, 齊藤雄二, 佐々木文彦, 平田正敏, 吉川充史, 藤田志保, 今村基尊
    平成20年度~平成22年度総括研究報告書, 67-72, 2011  
  • Kojima Shigeko, Saito Ayako, Shibayama Kenzo, Hayashi Masamichi, Saito Yuji, Sakakibara Hiroki
    The Journal of the Japan Society for Respiratory Care and Rehabilitation, 20(2) 152-155, 2010  
  • 榊原博樹, 井水ひろみ, 三重野ゆうき, 林 正道, 齊藤雄二, 平田正敏, 吉川充史, 藤田志保
    呼吸不全に関する調査研究班 平成21年度研究報告書別冊、厚生労働科学研究・難治性疾患克服研究事業, 280-284, 2010  
  • Yoshitaka Totani, Yuji Saito, Masamichi Hayashi, Toshihiko Tada, Yasuo Kohashi, Yuki Mieno, Atsushi Kato, Hiromi Imizu, Yukiko Yoneda, Tami Hoshino, Yasuhiro Uchiyama, Yasuo Takeuchi, Mitsushi Okazawa, Hiroki Sakakibara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 64(6) 1181-1185, Nov, 2009  Peer-reviewed
    To assess the efficacy and toxicity of an oral anticancer fluoropyrimidine derivative, S-1, for previously treated patients with advanced non-small cell lung cancer (NSCLC). Patients with advanced (clinical stage IIIB-IV) NSCLC who had previously received one platinum-based chemotherapy were enrolled. S-1 was administered orally at the dosage decided by using the nomogram based on patient BSA b.i.d. for 28 consecutive days, repeated every 6 weeks. Between August 2005 and July 2007, 50 patients were entered into this study. Six patients achieved partial response (PR), and the overall response rate of eligible patients was 12.5% (6/48) (95% confidence interval (95%CI), 3.1-21.9%). Disease control rate was 39.6% (19/48) (95%CI, 25.7-53.4%). Median progression-free survival was 2.5 months. Median survival time was 8.2 months, and 1-year survival rate was 29.6%. No grade 4 toxicities were encountered. Grade 3 hematological toxicities comprised neutropenia in one patient (2.1%) and anemia in one patient (2.1%). Grade 3 non-hematological toxicities were observed in only five patients (10.4%). Treatment-related death did not occur. S-1 is an active and well-tolerated monotherapy for second-line treatment of advanced NSCLC.
  • 小橋保夫, 齊藤雄二, 戸谷嘉孝, 米田有希子, 林 正道, 岡澤光芝, 榊原博樹
    日本呼吸器学会誌, 47(4) 265-270, 2009  
  • 榊原博樹, 井水ひろみ, 三重野ゆうき, 内山康裕, 林 正道, 齊藤雄二, 佐々木文彦, 平田正敏, 吉川充史, 藤田志保
    平成20年度研究報告書, 252-262, 2009  

Books and Other Publications

 5

Presentations

 75